0001209191-22-051637.txt : 20220930
0001209191-22-051637.hdr.sgml : 20220930
20220930162350
ACCESSION NUMBER: 0001209191-22-051637
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20220928
FILED AS OF DATE: 20220930
DATE AS OF CHANGE: 20220930
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Reddoch James F.
CENTRAL INDEX KEY: 0001814872
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-39329
FILM NUMBER: 221284357
MAIL ADDRESS:
STREET 1: C/O ROYALTY PHARMA PLC
STREET 2: 110 EAST 59TH STREET
CITY: NEW YORK
STATE: NY
ZIP: 10022
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Royalty Pharma plc
CENTRAL INDEX KEY: 0001802768
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 000000000
STATE OF INCORPORATION: X0
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 110 EAST 59TH STREET
CITY: NEW YORK
STATE: NY
ZIP: 10022
BUSINESS PHONE: (212) 883-0200
MAIL ADDRESS:
STREET 1: 110 EAST 59TH STREET
CITY: NEW YORK
STATE: NY
ZIP: 10022
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2022-09-28
0
0001802768
Royalty Pharma plc
RPRX
0001814872
Reddoch James F.
C/O ROYALTY PHARMA PLC
110 E. 59TH STREET
NEW YORK
NY
10022
0
1
0
0
EVP & Chief Scientific Officer
Class A Ordinary Shares
2022-09-28
4
S
0
100000
41.2267
D
820800
I
By Reddoch RPI LLC
Class A Ordinary Shares
25030
I
By IRA
LP interests in RPI US Partners 2019, LP
2022-08-12
5
G
0
E
2400
0.00
D
Class A Ordinary Shares
24000
478870
I
By Reddoch RPI LLC
The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $41.03 to $41.57 per share. The holder undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
No limited partnership interests in RPI US Partners 2019, LP ("RPI US LP") are being exchanged by the Reporting Person. Each limited partnership interest in RPI US LP ("RPI US LP Interest") may be exchanged for ten Class B Interests in Royalty Pharma Holdings Limited ("Holdings"). Each Class B Interest in Holdings so distributed will be exchanged for one Class A Ordinary Share of the Issuer. Any exchanges will be made pursuant to the terms of the Exchange Agreement dated June 16, 2020, among the Issuer, Holdings, RPI US LP, RPI International Holdings 2019, LP, RPI International Partners 2019, LP and RPI EPA Holdings, LP (the "Exchange Agreement"). No additional value will be paid by the Reporting Person in connection with an exchange.
The Reporting Person made a charitable donation of RPI US LP Interests. No Class A Ordinary Shares or RPI US LP Interests were sold.
Represents RPI US LP Interests. Each RPI US LP Interest can be exchanged for ten Class B Interests in Holdings at any time and for no additional value, which exchange right does not expire until so converted. Upon such exchange, each Class B Interest in Holdings issued in exchange for a RPI US LP Interest will be exchanged for one Class A Ordinary Share of the Issuer for no additional value.
The Reporting Person has agreed to retain and not sell 478,870 RPI US LP Interests convertible into 4,788,700 Class A Ordinary Shares before February 2025 pursuant to an agreement by and between the Reporting Person and RP Management, LLC. This restriction is waivable under certain circumstances.
/s/ Sean Weisberg, as Attorney-in-Fact for James F. Reddoch
2022-09-30